MISSION, Kan., April 23, 2018 -- Study focuses on early detection of Alzheimer’s disease and tracking it over time
African Americans are twice as likely to develop Alzheimer's disease
|
|||||
(Family Features) More than 5 million Americans are suffering from Alzheimer’s disease, and scientists expect this number to triple by 2050. Experts say that African Americans are two to three times more likely than white Americans to develop the disease. A momentous scientific study focused on early detection of Alzheimer’s disease, and tracking it over time, seeks healthy volunteers without memory problems, as well as people who have mild memory problems, and those who have been diagnosed with mild dementia due to Alzheimer’s disease.
The prestigious Alzheimer’s Disease Neuroimaging Initiative – or ADNI – funded by the National Institutes of Health, is one of the largest and longest running Alzheimer’s disease trials in history. Now in the third phase of trials, researchers are studying how quickly things like reasoning and the ability to perform certain functions change in the aging brain. Researchers need to better understand the disease progression in order to speed the pace of discovery in the race to prevent, treat and cure Alzheimer’s disease.
“It is extremely important that more African Americans get involved in the fight against Alzheimer’s disease, which affects nearly all of us in some way,” said Michael Weiner, MD, principal investigator of the study. “We need to know why and how Alzheimer’s disease progresses in African Americans in order to discover new treatments that could significantly improve the way we treat it in the future.”
The study uses state-of-the-art imaging to monitor brain levels of two proteins called tau and amyloid, both of which are significant indicators of Alzheimer’s disease. Researchers track cognitive function through computer tests at home and in a doctor’s office, which includes measuring changes in one’s ability to handle money, a common warning sign of the disease.
“One of the biggest challenges researchers face is finding people to volunteer to take part in studies,” said Weiner. “We can beat Alzheimer’s, but we can’t do it without volunteers.”
The ADNI Study needs 800 people to enroll in sites across the United States and in Canada. Researchers are looking for people between the ages of 55 and 90 who have normal thinking and memory function, as well as those who have mild memory problems and those who have been diagnosed with mild dementia due to Alzheimer’s disease. No medication is involved.
Potential study volunteers can learn more by visiting www.ADNI3.org or by calling 1-888-2-ADNI-95 (1-888-223-6495).
Michael French
[email protected]
1-888-824-3337
editors.familyfeatures.com
About Family Features Editorial Syndicate
Established in 1974, Family Features is a leading provider of free food and lifestyle content for print and online publications. Our articles, photos, videos and web content solutions save you time, money and help create advertising opportunities. Registration is fast and free – with absolutely no obligation. Visit editors.familyfeatures.com for more information.
A photo accompanying this announcement is available at http://resource.globenewswire.com/Resource/Download/4b17c06f-6ac7-485a-913c-f78974387f18


OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 



